Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Epigenomics AG    ECX   DE000A11QW50

EPIGENOMICS AG

(ECX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
02/24/2020 02/25/2020 02/26/2020 02/27/2020 02/28/2020 Date
1.49(c) 1.54(c) 1.535(c) 1.425(c) 1.385 Last
145 666 34 522 153 739 81 615 149 873 Volume
-5.40% +3.36% -0.32% -7.17% -2.81% Change
More quotes
Financials (EUR)
Sales 2019 1,20 M
EBIT 2019 -13,7 M
Net income 2019 -12,3 M
Finance 2019 7,46 M
Yield 2019 -
Sales 2020 6,40 M
EBIT 2020 -14,3 M
Net income 2020 -13,6 M
Debt 2020 7,47 M
Yield 2020 -
P/E ratio 2019 -4,13x
P/E ratio 2020 -4,06x
EV / Sales2019 44,2x
EV / Sales2020 10,6x
Capitalization 60,3 M
More Financials
Company
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The... 
More about the company
Surperformance© ratings of Epigenomics AG
Trading Rating : Investor Rating :
More Ratings
Latest news on EPIGENOMICS AG
05:05pEPIGENOMICS : Centers for Medicare & Medicaid Services open NCD review process f..
EQ
01/21EPIGENOMICS AG : Release according to Article 40, Section 1 of the WpHG [the Ger..
EQ
01/07EPIGENOMICS AG : Release according to Article 40, Section 1 of the WpHG [the Ger..
EQ
2019Epigenomics AG Reports on New Micro-Simulation Study Results Published in Can..
GL
2019EPIGENOMICS AG : Epigenomics AG Reports on New Micro-Simulation Study Results Pu..
EQ
2019EPIGENOMICS AG : New Micro-Simulation Study in Cancer Medicine Finds Epi proColo..
EQ
2019New Micro-Simulation Study in Cancer Medicine Finds Epi proColon® Provides Cl..
GL
2019EPIGENOMICS AG : Release according to Article 40, Section 1 of the WpHG [the Ger..
EQ
2019EPIGENOMICS AG : Correction of a release from 15/11/2019 according to Article 40..
EQ
2019EPIGENOMICS : Reports Financial Results for the First Nine Months 2019
EQ
2019EPIGENOMICS AG : Release according to Article 40, Section 1 of the WpHG [the Ger..
EQ
2019EPIGENOMICS : Announces Conference Call with Authors Presenting at the European ..
EQ
2019EPIGENOMICS AG : Notification and public disclosure of transactions by persons
EQ
2019EPIGENOMICS AG : Release according to Article 41 of the WpHG [the German Securit..
EQ
2019EPIGENOMICS AG : Release according to Article 40, Section 1 of the WpHG [the Ger..
EQ
More news
News in other languages on EPIGENOMICS AG
05:05pEPIGENOMICS : Centers for Medicare & Medicaid Services eröffnen NCD-Prüfungsproz..
05:03pCenters for Medicare & Medicaid Services eröffnen NCD-Prüfungsprozess für Epi..
2019EPIGENOMICS : berichtet über Ergebnisse einer Mikrosimulationsstudie, die zeigen..
2019Epigenomics berichtet über Ergebnisse einer Mikrosimulationsstudie, die zeige..
2019EPIGENOMICS AG : Neue Mikrosimulationsstudie zeigt, dass Epi proColon(R) eine kl..
More news
Chart EPIGENOMICS AG
Duration : Period :
Epigenomics AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EPIGENOMICS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 3,95  €
Last Close Price 1,39  €
Spread / Highest target 225%
Spread / Average Target 185%
Spread / Lowest Target 145%
EPS Revisions
Managers
NameTitle
Gregory K. Hamilton Chief Executive Officer
Jorge A. Garces President & Chief Scientific Officer
Heino von Prondzynski Chairman-Supervisory Board
Günther Reiter Vice Chairman-Supervisory Board
Ann Clare Kessler Member-Supervisory Board
Sector and Competitors